Skip to main content
73°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Tempus
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib
June 26, 2024
From
Tempus
Via
Business Wire
Tickers
TEM
Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension
June 25, 2024
From
Tempus
Via
Business Wire
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
June 02, 2024
From
Tempus
Via
Business Wire
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
June 01, 2024
From
Tempus
Via
Business Wire
Tempus Announces the Clinical Launch of its MRD Testing Portfolio
May 31, 2024
From
Tempus
Via
Business Wire
Tempus Introduces its AI-enabled Care Pathway Intelligence Platform, Tempus Next
April 16, 2024
From
Tempus
Via
Business Wire
Tempus Releases New Data at AACR Showcasing Ways to Analyze Multimodal Data to Highlight Potential Therapeutic Routes for HER2-Directed Antibody-Drug Conjugates in Several Tumor Types
April 08, 2024
From
Tempus
Via
Business Wire
Tempus Introduces Workspaces into its Lens Data Analytics Platform
April 06, 2024
From
Tempus
Via
Business Wire
Tempus Announces 18 Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2024
April 05, 2024
From
Tempus
Via
Business Wire
Tempus Contributes De-Identified Cancer Data to Planned Data Enclave
March 14, 2024
From
Tempus
Via
Business Wire
Tempus Expanding Access to its Next-Generation Sequencing Tests as an In-Network Provider for Cigna
February 21, 2024
From
Tempus
Via
Business Wire
Tempus Introduces AI-enabled Assistant, Tempus One, Into Lens Data Analytics Platform to Accelerate Research
February 02, 2024
From
Tempus
Via
Business Wire
Tempus is Now an In-Network Provider for Humana, Expanding Access to its Next-Generation Sequencing Tests
January 24, 2024
From
Tempus
Via
Business Wire
Tempus Introduces xM to Assess Minimal Residual Disease (MRD) in Patients with Colorectal Cancer (CRC) for Research Use Only
January 18, 2024
From
Tempus
Via
Business Wire
Tempus Announces Medicare Coverage for Tempus|xT Across Solid Tumor and Hematologic Malignancies
November 15, 2023
From
Tempus
Via
Business Wire
Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches
November 08, 2023
From
Tempus
Via
Business Wire
Tempus Announces New ctDNA Assay, xF Monitor
November 03, 2023
From
Tempus
Via
Business Wire
FDA Grants Breakthrough Device Designation To Tempus’ HLA-LOH Companion Diagnostic Test
August 15, 2023
From
Tempus
Via
Business Wire
Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study
July 12, 2023
From
Tempus
Via
Business Wire
Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics
July 06, 2023
From
Tempus
Via
Business Wire
Tempus Announces Broad Launch of Tempus One
June 01, 2023
From
Tempus
Via
Business Wire
Tempus Announces Dr. Ned Sharpless as a Senior Strategic Advisor
May 10, 2023
From
Tempus
Via
Business Wire
Tempus Receives U.S. FDA Approval for xT CDx, a NGS-Based In Vitro Diagnostic Device
May 01, 2023
From
Tempus
Via
Business Wire
Tempus Announces New Strategic Collaboration with Pfizer to Advance Oncology Therapeutic Development
February 28, 2023
From
Tempus
Via
Business Wire
Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer
January 05, 2023
From
Tempus
Via
Business Wire
Tickers
AZN
Tempus Launches First Cardiology Prospective Study for Its AI-Enabled Predictive Tests
November 03, 2022
From
Tempus
Via
Business Wire
Tempus Announces Real-World Data-Driven Program to Accelerate Precision Oncology Research
October 27, 2022
From
Tempus
Via
Business Wire
Tempus Announces Companion Diagnostic Collaboration with Kartos Therapeutics
October 06, 2022
From
Tempus
Via
Business Wire
Tempus Announces Three Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2022
September 09, 2022
From
Tempus
Via
Business Wire
Tempus Announces Sequencing Collaboration With Lilly to Expand Access to Genomic Testing
June 09, 2022
From
Tempus
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.